Revolutions Medical announces completion of designs for 5ml and 10ml fixed needle RevVac Safety Syringes

Revolutions Medical CorporationNov 3 2010

Revolutions Medical Corporation (OTCBB:RMCP) announced today that due to the launch of its 3ml RevVac Safety Syringe^TM during the Medica show in Dusseldorf, Germany and the enormous interest that the launch has received from healthcare professionals and corporations in Europe, the company will host an additional reception in London on Saturday, November 20th from 7:30 PM - 9:30 PM at the Landmark Hotel, Tower Suite. Anyone interested in attending the reception can RSVP on the company's website at www.revolutionsmedical.com.

With the recent passage of legislation in the European Union (EU) on new requirements to prevent accidental needlestick injuries, the EU is sending the directive to make the work environment safer for healthcare professionals. There are over 1 million accidental needlestick injuries every year in Europe. The costs associated with the lab testing, treatment, recovery and work stoppage from these needlesticks have been skyrocketing, not to mention the anxiety and hardships for the healthcare professional. Ron Wheet, the company's CEO, stated: "We believe that our RevVac Safety Syringe can virtually eliminate these accidental needlestick injuries and the spread of potentially fatal blood borne diseases such as HIV, Hepatitis B and C." For more information, go to these two links http://www.healthfirsteurope.org and http://www.paramedicpractice.com/comment.

Mr. Wheet added: "I am very pleased that we have completed the designs for both the 5ml and 10ml fixed needles before we head to Europe to introduce and launch sales for our 3ml RevVac Safety Syringe. We plan to complete our RevLok^TM interchangeable needle design for the 3, 5 and 10ml sizes, along with the fixed needle 1ml design, by the end of the first quarter of 2011. We also see a significant opportunity in the rapidly growing prefilled syringe market segment and are working diligently on a prefilled syringe product line using our patented vacuum technology designs." Mr. Wheet continued: "One of our goals for 2011 is to be able to manufacture and roll out these additional products to capture these lucrative markets."